Baidu
map

中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组成立大会曁新丝绸之路肿瘤姑息治疗巡讲——西安站

2016-05-28 MedSci MedSci原创

在中国抗癌协会癌症康复与姑息治疗专业委员会的大力支持与帮助下,在陕西省抗癌协会和陕西省肿瘤医院领导的关心协助下,于2016年5月22日由陕西省肿瘤医院吴敏慧首先倡导并与宁夏医科大学总医院王宁菊、兰州大学医学院第一附属医院赵达、新疆自治区人民医院柳江、青海医科大学附属医院赵君慧共同发起的中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组成立大会曁新丝绸之路肿瘤姑息治疗巡讲(西安站),


在中国抗癌协会癌症康复与姑息治疗专业委员会的大力支持与帮助下,在陕西省抗癌协会和陕西省肿瘤医院领导的关心协助下,于2016年5月22日由陕西省肿瘤医院吴敏慧首先倡导并与宁夏医科大学总医院王宁菊、兰州大学医学院第一附属医院赵达、新疆自治区人民医院柳江、青海医科大学附属医院赵君慧共同发起的中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组成立大会曁新丝绸之路肿瘤姑息治疗巡讲(西安站),在中国抗癌协会癌症康复与姑息治疗专业委员会主办,陕西省抗癌协会、陕西省肿瘤医院承办的中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组成立大会曁新丝绸之路肿瘤姑息治疗巡讲(西安站)在西安成功举办。会议由陕西省抗癌协会理事长主持,陕西省卫计委副主任孙振林、陕西省抗癌协会名誉理事长原陕西省卫计委副主任黄立勋、中国抗癌协会癌症康复与姑息治疗专业委员会主任委员王杰军、陕西省肿瘤医院院长宋张骏、陕西省抗癌协会秘书长薛刚到会并做了重要讲话。


陕西省卫计委   孙振霖副主任

很高兴见证了中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组的成立,并对该协作组的成立表示祝贺、对来自西部5省的专家表示热烈的欢迎。随后讲到医学乃人学,医术乃仁术,所以肿瘤治疗更多的应该处处彰显和充满人文关怀,不仅关注患者生理病理变化,更应该关注病人的主观感受和心理变化,对于晚期肿瘤患者应以改善生活质量,延长生存期为追求目标。希望该协作组的成立,让西部5省的专家相互协作,互通有无,更好的探索适合西部的姑息治疗途径,使生物医学模式真正转变成生物---心理---社会医学模式。


陕西省抗癌协会名誉理事长原陕西省卫计委副主任   

黄立勋他强调肿瘤患者的治疗中应体现人文关怀,关注患者肿瘤治疗的同时,更要关注生活质量和患者的人格尊严,中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组的成立,给陕西及西部的癌症患者带来了福音,希望中国抗癌协会康复与姑息治疗专业委员会一如既往的支持和指导该协作组的工作,更好的服务于肿瘤患者。



中国抗癌协会癌症康复与姑息治疗专业委员会主任委员   王杰军教授

癌症康复与姑息治疗在我国起步较晚,但近几年在致力于姑息治疗专家的努力下,在癌痛规范化治疗示范病房项目的推动下,工作有了长足的进步,有些省市已经将阿片类药物列入基本用药目录,取消了一品双规的管理规定,阿片类药物实行电子处方及电子签名管理;有些省市将阿片类药物不再纳入药占比;我们还将努力实现阿片类药物进入基层医院,真正使癌痛患者镇痛治疗实现院内、院外、居家治疗无缝对接。感谢西部专家为姑息治疗工作所做的努力,我们也希望癌症姑息治疗西部协作组的成立,能率先尝试姑息治疗路径的建立,探索并总结经验,在全国推广,祝协作组的团队精诚协作,相互交流,工作越做越好。


陕西省肿瘤医院   宋张骏院长

肿瘤的治疗现状是偶尔治愈,常常帮助,总是安慰,镇痛及症状处理等是我们医生每天都要面临的问题,姑息治疗几乎涵盖了所有肿瘤治疗范畴。近几年我们以中西医结合科为主,在癌痛规范化治疗示范病房创建工作中以及肿瘤姑息治疗工作积累了一些经验,也使肿瘤患者享受了他们应该享受的尊严。面对晚期癌症患者,常常会对我们的人格提出挑战,我们医务工作者如何在我们的工作中用规范化、人性化去帮助他们从新获得生命的尊严,是我们每个医生应该思考的问题,欢迎西部的专家到陕西省肿瘤医院交流与指导工作,相互提高肿瘤诊治水平。各级领导及学会对癌症康复与姑息治疗工作的重视及落实国家卫计委提出的“关于加强肿瘤规范诊疗管理工作的通:癌症的康复与姑息治疗知”的具体体现。中国抗癌协会癌症康复与姑息治疗专业委员会西部协作组成立标志着癌症康复与姑息治疗在西部一个新起点,这个学术平台的建立,将会进一步加快西部5省的癌症姑息规范化治疗知识的普及和临床研究的步伐,探寻适合西部经济和患者需求的姑息治疗路径,更好的服务于肿瘤患者。本次会议是西北5省(陕、甘、宁、青、新疆)癌症康复与姑息治疗的一次盛会,有国内4名姑息领域的专家,就肿瘤患者的癌痛管理营养支持、骨转移专家共识、中医药姑息治疗等话题进行了深入讲解及热烈的讨论,来自5省的从事肿瘤治疗和护理人员150余人参会。本次会议的成功举办,标准者协作组从西安为起点,沿着新丝绸之路,把癌症康复与姑息治疗的理念、知识、新进展传播到基层,让更多医护人员掌握规范化治疗,加快癌症姑息治疗体系的形成,并为建立医院姑息治疗亚学科打下坚实的基础,使肿瘤患者拥有更好的生活质量。

陕西省肿瘤医院   吴敏慧教授

介绍了协作组筹建及工作纲要,在中国抗癌谢会癌症康复与姑息治疗专业委员会的领导下和省级学会的指导下开展工作,协作组主要从临床研究、技术扶持、继续教育、流行病学调研等方面相互协作,达到资源共享,互通有无,探寻一条符合西部经济状况和患者需求的姑息临床路径;积极参与总会和地方学会的各项工作和指令性任务,更好的服务于患者是我们不懈的追求。

学术交流在西京医院刘文超教授、唐都医院张贺龙教授、宁夏医科大学总医院王宁菊、兰州大学医学院第一附属医院赵达的主持下完成。


北京大学肿瘤医院   刘巍教授

《癌痛药物治疗发展40年》她详述了癌痛药物治疗走过的40年发展之路,强调癌痛治疗的今天,应该是医生、护士、家庭/照护的全员参与的过程,癌痛的规范治疗应该包括疼痛筛查、疼痛评估、疼痛诊断、规范治疗、动态评估、宣教随访、门诊治疗等全程管理,同时还应注重舒适镇痛的个体化治疗。


新疆自治区人民医院   柳江教授

《恶性肿瘤骨转移及相关疾病临床诊疗专家共识》恶性肿瘤骨转移发病率高,严重影响患者的生活质量和生存期。强调恶性肿瘤骨转移的诊断及鉴别诊断、骨相关风险的评估、规范化治疗,同时将不同治疗的药物不良反应和放疗、核素治疗的应用疗效、副作用的方面进行了详细的阐述。


西京医院   张红梅教授

《肿瘤患者营养评估和治疗》肿瘤患者的营养不良在晚期患者中发生率高,也是近几年肿瘤专科医生在姑息治疗中关注的焦点之一。张教授详细的介绍了癌症病人营养评估的方法及重要性,重点讲述了癌症患者营养不良的治疗,改变了既往对营养治疗的传统观念,并引发了热烈的讨论。


陕西省肿瘤医院   吴敏慧教授

《中医药在肿瘤姑息治疗中的地位和应用》她公布了癌症患者在治疗中,应用中药治疗的比例高达80%,不规范使用的现象非常普遍,严重影响中药的疗效。中医药在肿瘤患者姑息治疗中发挥着不可或缺的作用。与手术、化疗、放疗、靶向治疗配合,能达到减毒增效,减轻状况,提高生活质量的功效。强调应辩证施治,方可达到治疗目的。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 lsblb

    不错不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 milkshark

    不错不错

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
    2016-05-30 milkshark

    形式很好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2034252, encodeId=2b5a203425207, content=<a href='/topic/show?id=1fe6828956d' target=_blank style='color:#2F92EE;'>#肿瘤姑息治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82895, encryptionId=1fe6828956d, topicName=肿瘤姑息治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Wed Feb 15 04:04:00 CST 2017, time=2017-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138072, encodeId=45561380e2c2, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 14:38:43 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1972835, encodeId=fb7919e28358b, content=<a href='/topic/show?id=639121868f8' target=_blank style='color:#2F92EE;'>#中国抗癌协会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21868, encryptionId=639121868f8, topicName=中国抗癌协会)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Sat Dec 24 23:04:00 CST 2016, time=2016-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87658, encodeId=9d778e658fc, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f9f21613855, createdName=lsblb, createdTime=Mon May 30 19:24:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87478, encodeId=3a6a8e478f7, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=87479, encodeId=09838e47902, content=形式很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7cde98330, createdName=milkshark, createdTime=Mon May 30 06:43:00 CST 2016, time=2016-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626624, encodeId=afb41626624f0, content=<a href='/topic/show?id=2d91449540c' target=_blank style='color:#2F92EE;'>#姑息#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44954, encryptionId=2d91449540c, topicName=姑息)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adea21051784, createdName=经常头晕, createdTime=Mon May 30 04:04:00 CST 2016, time=2016-05-30, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map